GlassScriptPhysician profile
Gina Kirk
NPI 1811982127
$1,988.17
in general payments reported to CMS, 2019-2025
21 companies · $649 in 2025
The $649 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $291 · 2022: $291 · 2023: $262 · 2024: $497 · 2025: $649.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,407.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,406.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $481.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $248.99 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Lilly USA, LLC | $246.84 | 2021-2025 | Mounjaro, Zepbound |
| Amgen INC. | $208.45 | 2023-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $190.01 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $75.04 | 2022-2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $65.37 | 2021-2023 | |
| Esperion Therapeutics, INC. | $64.93 | 2022-2025 | Nexletol |
| Exact Sciences Corporation | $62.87 | 2023-2024 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $52.79 | 2023-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $51.88 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $41.33 | 2021 | |
| Merck Sharp & Dohme LLC | $37.92 | 2024-2025 | Capvaxive, Gardasil 9, M-M-R II |
| Antares Pharma, INC. | $37.02 | 2022-2024 | Xyosted |
| Abbott Laboratories | $23.89 | 2024 | Freestyle Libre |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.73 | 2025 | Keveyis |
| Bayer Healthcare Pharmaceuticals INC. | $18.56 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.10 | 2021 | |
| Sanofi-Aventis U.S. LLC | $15.18 | 2025 | |
| Sanofi Pasteur INC. | $14.33 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $14.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gina Kirk listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.